Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis

CAMBRIDGE, Mass., May 17, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced two data presentations supporting plans for rapid development of avapritinib, a selective KIT and PDGFR? inhibitor, in patients with gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM).

Data from a retrospective natural history study of previously treated patients with advanced PDPGFR? D842V-driven GIST will be presented in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 1-5, 2018. In addition, updated data from Blueprint Medicines' Phase 1 EXPLORER trial of avapritinib in patients with advanced SM will be presented in a poster session at the 23^rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden on June 14-17, 2018. 

The accepted abstracts are listed below and are now available online on the ASCO and EHA conference websites, respectively: https://am.asco.org/ and https://ehaweb.org/congress/23rd-c/key-information/. 

2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Presentation Title: A retrospective natural history study of patients (pts) with PDGFR? D842V mutant advances gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI)
Session Title: Sarcoma
Session Date & Time: Saturday, June 2, 2018 from 8:00 a.m. ? 11:30 a.m. CT (9:00 a.m. ? 12:30 p.m. ET)
Abstract Number: 11533
Poster Board Number: 278
Location: Hall A, McCormick Place

23rd Congress of the European Hematology Association (EHA)

Presentation Title: Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis (AdvSM): Results of a Phase 1 Study 
Session Title: Myeloproliferative neoplasms - Clinical
Session Date & Time: Friday, June 15, 2018 from 17:30 ? 19:00 CEST (11:30 a.m. ? 1:00 p.m. ET)
Abstract Number: PF612
Location: Poster Area, Stockholmsmässan

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases. Blueprint Medicines is advancing multiple programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

SOURCE Blueprint Medicines